This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |
| tacrolimus [2025/06/14 04:23] – [Resources] Scott Larson | tacrolimus [2025/06/14 04:24] (current) – [Resources] Scott Larson |
|---|
| |
| ==== Resources ==== | ==== Resources ==== |
| * <wrap em>{{::tacrolimus_dermatologic_package_insert_fda.pdf|FDA package insert for Tacrolimus}}</wrap> | * <wrap em>[[https://1drv.ms/b/c/31d83ae8e55e0542/EfUdSFGpXaVLoJmDHQ6K3fwBDNGgZC2B1JAau8u9LByjPw?e=zE88VD|FDA package insert for Tacrolimus]]</wrap> |
| * [[https://1drv.ms/b/c/31d83ae8e55e0542/ERPuYT3qeXBDlKCoNmMz4HYBbH0ZvORoGVjNZhVC09HrFQ?e=dh5VA6|Hazarika AK et al. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Natural Science, Biology and Medicine 2015;6(1):S10-12]] | * [[https://1drv.ms/b/c/31d83ae8e55e0542/ERPuYT3qeXBDlKCoNmMz4HYBbH0ZvORoGVjNZhVC09HrFQ?e=dh5VA6|Hazarika AK et al. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Natural Science, Biology and Medicine 2015;6(1):S10-12]] |
| * [[https://1drv.ms/b/c/31d83ae8e55e0542/EYz_NyvwrhZBkod4KFxRlYgB_5d68x49Y7IIh8Ke-JQx7g?e=OdikWJ|Fukushima A et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmology 2014;98-1023-1027]] | * [[https://1drv.ms/b/c/31d83ae8e55e0542/EYz_NyvwrhZBkod4KFxRlYgB_5d68x49Y7IIh8Ke-JQx7g?e=OdikWJ|Fukushima A et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmology 2014;98-1023-1027]] |